Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • GeneQuine and Panion are exploring a licensing agreement for osteoarthritis gene therapy in horses and dogs
  • Malaysian conglomerate NSDA has bought an exclusive license to Oxford BioDynamics’ EpiSwitch platform to accelerate drug delivery
  • Anagenesis has caught the eye of Boehringer Ingelheim, leading to a drug discovery deal for chronic muscle diseases
Oleksii G
  • Shire had a phenomenal week in the clinic, with stellar Phase III data in hereditary angioedema such that the drug has the makings of a blockbuster, and positive Phase II data for its antibody to treat moderate-to-severe ulcerative colitis
  • Roche published early clinical data from a bispecific antibody for metastatic colorectal cancer, suggesting it could boost existing therapies for hard-to-treat tumors
Brian Lasenby
  • European regulators have entered the drug pricing fray by opening an antitrust investigation into South African Aspen Pharmacare’s business practices
  • The Karolinska Institutet has described the spread of tau pathology in Alzheimers patients and shown that it can be linked to memory impairment

Images from Brian Lasenby, Eric Axelson, Marco Diaz Segura, Oleksii G / shutterstock.com
Previous post

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Next post

The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection